Provided by Tiger Trade Technology Pte. Ltd.

Tevogen Bio Holdings

0.2894
+0.00020.07%
Post-market: 0.2700-0.0194-6.70%19:58 EST
Volume:1.11M
Turnover:326.68K
Market Cap:58.32M
PE:-1.54
High:0.2980
Open:0.2900
Low:0.2749
Close:0.2892
52wk High:1.51
52wk Low:0.2301
Shares:201.52M
Float Shares:25.36M
Volume Ratio:2.97
T/O Rate:4.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1881
EPS(LYR):-0.0700
ROE:--
ROA:-439.67%
PB:-3.51
PE(LYR):-4.13

Loading ...

BRIEF-Tevogen Signs LOI To Evaluate Potential Acquisition Of Sciometrix

Reuters
·
13 hours ago

Tevogen Signs LOI to Evaluate Sciometrix Acquisition

Reuters
·
Yesterday

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and Its Digital Care Management Platform Clinicus

THOMSON REUTERS
·
Yesterday

Tevogen Bio Holdings Inc - Acquisition Would Give Tevogen Majority Voting Interest in Sciometrix

THOMSON REUTERS
·
Yesterday

Tevogen Bio Holdings Inc - Deal Could Make Tevogen Revenue-Generating Healthcare Enterprise

THOMSON REUTERS
·
Yesterday

Tevogen Bio Holdings Inc. Held Special Stockholder Meeting

Reuters
·
Yesterday

Press Release: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Dow Jones
·
Jan 31

Tevogen Bio Ties Long-Term Stock Incentives to Company Milestones

Reuters
·
Jan 30

Tevogen Bio Holdings Inc. Announces Date for Special Stockholder Meeting

Reuters
·
Jan 17

Tevogen Bio Expands T Cell Therapy Pipeline and Boosts Manufacturing Capacity

Reuters
·
Jan 12

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 20, 2025

Top News Today: Stocks Mixed as AI Selloff Slows

Dow Jones
·
Nov 15, 2025

Press Release: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Dow Jones
·
Nov 15, 2025

Tevogen announces clinical milestone in evolution of ExacTcell platform

TIPRANKS
·
Nov 06, 2025

Tevogen Bio Expands Precision T Cell Therapy Eligibility With Multi-HLA Targeting

Reuters
·
Nov 06, 2025

Tevogen Reports Major Clinical Milestone: Expands Hla Coverage of Its Investigational Precision T Cell Therapy for Acute and Long Covid

THOMSON REUTERS
·
Nov 06, 2025

Tevogen Bio Says Stockholders' Deficit is Under $9.5M

Dow Jones
·
Nov 04, 2025

Tevogen Bio Holdings Inc - Gaap Financials for Qtr Show $129 Mln Accumulated Deficit

THOMSON REUTERS
·
Nov 04, 2025

BRIEF-Tevogen Says Actively Preparing For Next Stage Of Development Of TVGN 489

Reuters
·
Oct 16, 2025

Tevogen: Intends to Collaborate With Govt Initiatives, Long Covid Patient Organizations, Healthcare Providers to Expedite Development of Tvgn 489

THOMSON REUTERS
·
Oct 16, 2025